Amycretin Phase 2 trial (NCT06064006)
A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or Obesity
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 125
- actual
- Start
- 15 Sep 2023 (actual)
- Primary completion
- 27 Nov 2024 (actual)
- Sponsor
- Novo Nordisk A/S
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| NNC0487-0111 | Experimental | Drug: NNC0487-0111; Drug: Placebo (NNC0487-0111) | Participants will be randomized to receive NNC0487-0111. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD) |
| Placebo | Placebo comparator | Drug: NNC0487-0111; Drug: Placebo (NNC0487-0111) | Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B,C,D and E: Multiple ascending dose (MAD). |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| PART A: Number of treatment emergent adverse events (TEAE) | From pre-dose on Day 1 until completion of the end of study visit, up to Day 25 |
| PARTS B to E: Number of treatment emergent adverse events (TEAE) | From pre-dose on Day 1 until completion of the end of study visit (V37) up to Day 270 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| PART A: AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose | From pre-dose on Day 1 until completion of the end of study visit, up to Day 25 |
| PART A: Cmax,SD; the maximum plasma concentration of NNC0487-0111 after a single dose and the corresponding time tmax | From pre-dose on Day 1 until completion of the end of study visit, up to Day 25 |
| PARTS B to E: AUC0-168h,SS; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to 168 hours after last multiple dose | From pre-dose on V33D1 until end of treatment (V34) up to 9 days |
| PARTS B to E: Cmax,SS; the maximum plasma concentration of NNC0487-0111 after last multiple dose and the corresponding time tmax | From pre-dose on V33D1 until end of study visit (V37) up to 24 days |
| PART B to E: Relative change in body weight | From pre-dose on Day 1 until end of treatment (V34) up to Day 255 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.